Bogen O, Araldi D, Sucher A, Kober K, Ohara PT, Levine JD (2024) Isolectin B4 (IB4)-conjugated streptavidin for the selective knockdown of proteins in IB4-positive (+) nociceptors. Mol Pain doi: 10.1177/17448069241230419 PMID: 38246917
Objective: To address the need for selective transfection methods, the authors covalently linked isolectin B4 (IB4) to streptavidin and analyzed whether it could be used to study protein function in IB4(+)-nociceptors
Summary: Rats treated intrathecally with IB4-conjugated streptavidin complexed with biotinylated antisense oligonucleotides for protein kinase C epsilon (PKCε) mRNA werefound to have: (a) less PKCε in dorsal root ganglia (DRG), (b) reduced PKCε expression in IB4(+) but not IB4(–) DRG neurons, and (c) fewer transcripts of the PKCε gene in the DRG. This knockdown in PKCε expression in IB4(+) DRG neurons is sufficient to reverse hyperalgesic priming, a rodent model of chronic pain that is dependent on PKCε in IB4(+)- nociceptors.
Usage: For each intrathecal injection 2.3μL IB4-streptavidin (30 pmol of conjugate with 120 pmol of biotin binding sites), 1.2μL biotinylated ODN (c = 100 pmol/μl) and 16.5μL PBS were mixed (injection volume = 20μL),
Related Products: Streptavidin-ZAP (Cat. #IT-27), IB4-SAP (Cat. #IT-10)